{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:05:31Z","timestamp":1790924731215,"version":"4.1.0"},"reference-count":98,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chronic kidney disease is a major public health concern among people living with human immunodeficiency virus (PLWHIV) who are taking tenofovir disoproxil fumarate-based regimen. Despite the available evidence showing a high prevalence of CKD in this population, comprehensive pooled estimate of CKD among PLWHIV receiving TDF based regimen across the globe is lacking. Hence, the present systematic review aimed to provide a global pooled prevalence estimate of CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted a systematic review of literatures published between January 2000 and May 2024. Articles and grey literature were searched from the following databases and search engine: PubMed, EMBASE, Scopus, Web of science, The Cumulative Index to Nursing and Allied Health Literature (CINHAL), and Google Scholar. We included eligible studies that report magnitude of CKD in TDF based regimen. We executed the pooled CKD, subgroup analysis, and funnel plot using random effect model. All statistical analysis including sensitivity analysis were made using Stata 17 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-nine studies with 88299 participants included in this meta-analysis. The pooled prevalence of CKD was 7% (95% CI:6\u20138). CD4 count less than 200 copies per milliliter, and being female were associated with CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We concluded that the magnitude of CKD across the globe is high in people living with HIV who have received TDF based regimen. Early identification of CKD by considering regular renal function monitoring, and risk factors especially low CD4 count, and female gender at birth are essential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The protocol has been prospectively registered with PROSPERO ((\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020136813\" xlink:type=\"simple\">CRD42020136813<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0318068","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T13:42:38Z","timestamp":1738849358000},"page":"e0318068","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chronic kidney disease among people living with HIV on TDF based regimen: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1218-5826","authenticated-orcid":true,"given":"Taklo Simeneh","family":"Yazie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wondimeneh Shibabaw","family":"Shiferaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaye Alamneh","family":"Gebeyehu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7268-9722","authenticated-orcid":true,"given":"Assefa Agegnehu","family":"Teshome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenaw Debasu","family":"Addisu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abebe Muche","family":"Belete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"pone.0318068.ref001","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11904-016-0315-y","article-title":"Chronic kidney disease and antiretroviral therapy in HIV-positive individuals: recent developments","volume":"13","author":"AC Achhra","year":"2016","journal-title":"Current HIV\/AIDS Reports"},{"key":"pone.0318068.ref002","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/IJNRD.S93887","article-title":"Update on current management of chronic kidney disease in patients with HIV infection","volume":"9","author":"NE Diana","year":"2016","journal-title":"International Journal of Nephrology and Renovascular Disease"},{"issue":"4","key":"pone.0318068.ref003","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/cid\/cis937","article-title":"Association Between Tenofovir Exposure and Reduced Kidney Function in a Cohort of HIV-Positive Patients: Results From 10 Years of Follow-up","volume":"56","author":"C Laprise","year":"2012","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"pone.0318068.ref004","doi-asserted-by":"crossref","first-page":"e79885","DOI":"10.1371\/journal.pone.0079885","article-title":"WHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients","volume":"8","author":"D Mizushima","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"pone.0318068.ref005","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jiac.2018.03.002","article-title":"Tenofovir disoproxil fumarate co-administered with lopinavir\/ritonavir is strongly associated with tubular damage and chronic kidney disease","volume":"24","author":"D Mizushima","year":"2018","journal-title":"J Infect Chemother"},{"issue":"3","key":"pone.0318068.ref006","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/apc.2016.0286","article-title":"Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naive Asian Patients: Results from 12-Year Observational Cohort","volume":"31","author":"S Suzuki","year":"2017","journal-title":"AIDS Patient Care STDS"},{"issue":"5","key":"pone.0318068.ref007","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","article-title":"Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence","volume":"57","author":"AM Hall","year":"2011","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"pone.0318068.ref008","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jmii.2015.08.019","article-title":"Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients","volume":"50","author":"YS CC Huang","year":"2017","journal-title":"Journal of microbiology, immunology and infection"},{"issue":"4","key":"pone.0318068.ref009","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/09564624221076632","article-title":"Recovery of renal function after early versus late switching of tenofovir disoproxil fumarate in people living with HIV with renal insufficiency","volume":"33","author":"S JP Suppadungsuk","year":"2022","journal-title":"International journal of STD & AIDS"},{"issue":"5","key":"pone.0318068.ref010","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","article-title":"Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients","volume":"51","author":"RD Cooper","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0318068.ref011","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-019-0227-1","article-title":"Tenofovir-associated kidney disease in Africans: a systematic review","volume":"16","author":"TJ Mtisi","year":"2019","journal-title":"AIDS Res Ther"},{"issue":"7","key":"pone.0318068.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"A Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"pone.0318068.ref013","volume-title":"Joanna Briggs Institute reviewer\u2019s manual","author":"Z Munn","year":"2017"},{"issue":"4","key":"pone.0318068.ref014","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.ackd.2010.05.002","article-title":"The aging kidney: physiological changes","volume":"17","author":"JR Weinstein","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"pone.0318068.ref015","unstructured":"MOH. NATIONAL CONSOLIDATED GUIDELINES FOR COMPREHENSIVE HIV PREVENTION, CARE AND TREATMENT. Ethiopia2018."},{"key":"pone.0318068.ref016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement","volume":"75","author":"J McGowan","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"key":"pone.0318068.ref017","first-page":"1","volume-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"J Peterson","year":"2011"},{"key":"pone.0318068.ref018","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/9781119536604.ch8","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPT SJ Higgins","year":"2019","edition":"2"},{"issue":"7","key":"pone.0318068.ref019","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/0956462417749733","article-title":"Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi","volume":"29","author":"B Chikwapulo","year":"2018","journal-title":"Int J STD AIDS"},{"issue":"9","key":"pone.0318068.ref020","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1089\/aid.2022.0009","article-title":"Clinical Characteristics and Outcomes of Chronic Kidney Disease in People Living with HIV in a Resource-Limited Center of Central China","volume":"38","author":"L Feng","year":"2022","journal-title":"AIDS Research and Human Retroviruses"},{"issue":"8","key":"pone.0318068.ref021","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/nep.13100","article-title":"Chronic kidney disease in Australian Human Immunodeficiency Virus-infected patients: Analysis of the Australian HIV Observational Database","volume":"23","author":"J Cheung","year":"2018","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"pone.0318068.ref022","doi-asserted-by":"crossref","first-page":"e66223","DOI":"10.1371\/journal.pone.0066223","article-title":"Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004\u20132012","volume":"8","author":"P Morlat","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"pone.0318068.ref023","doi-asserted-by":"crossref","first-page":"e0141931","DOI":"10.1371\/journal.pone.0141931","article-title":"Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study","volume":"10","author":"T Nishijima","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"pone.0318068.ref024","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2014.10.013","article-title":"Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management","volume":"65","author":"A Akbari","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"pone.0318068.ref025","unstructured":"National STD \/ AIDS Control Programme and Ministry of Health SL. A Guide to Antiretroviral Treatment. Sri Lanka2020."},{"key":"pone.0318068.ref026","unstructured":"Services. DoHaH. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2024."},{"issue":"9","key":"pone.0318068.ref027","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","article-title":"Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement","volume":"65","author":"D Hoy","year":"2012","journal-title":"Journal of clinical epidemiology"},{"issue":"2","key":"pone.0318068.ref028","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"TB Huedo-Medina","year":"2006","journal-title":"Psychological methods"},{"key":"pone.0318068.ref029","doi-asserted-by":"crossref","DOI":"10.1002\/9781119099369","volume-title":"Systematic Reviews in Health Research: Meta-Analysis in Context","author":"M Egger","year":"2022"},{"issue":"2","key":"pone.0318068.ref030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"M Borenstein","year":"2010","journal-title":"Research synthesis methods"},{"issue":"8","key":"pone.0318068.ref031","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/QAD.0000000000000202","article-title":"Renal events among women treated with tenofovir\/emtricitabine in combination with either lopinavir\/ritonavir or nevirapine","volume":"28","author":"A Mwafongo","year":"2014","journal-title":"AIDS"},{"issue":"3","key":"pone.0318068.ref032","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3851\/IMP3097","article-title":"Evolution of renal function in African patients initiating second-line antiretroviral treatment: findings from the ANRS 12169 2LADY trial","volume":"22","author":"A Cournil","year":"2017","journal-title":"Antivir Ther"},{"issue":"1","key":"pone.0318068.ref033","doi-asserted-by":"crossref","first-page":"ofy273","DOI":"10.1093\/ofid\/ofy273","article-title":"Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ss2M in the ION-4 Study Cohort","volume":"6","author":"A Chan","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"pone.0318068.ref034","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dkaa008","article-title":"Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population","volume":"75","author":"M Neary","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"pone.0318068.ref035","doi-asserted-by":"crossref","first-page":"9172607","DOI":"10.1155\/2019\/9172607","article-title":"Reduced Kidney Function in Tenofovir Disoproxil Fumarate Based Regimen and Associated Factors: A Hospital Based Prospective Observational Study in Ethiopian Patients","volume":"2019","author":"TS Yazie","year":"2019","journal-title":"Int J Nephrol"},{"issue":"13","key":"pone.0318068.ref036","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1097\/QAD.0000000000000347","article-title":"Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up","volume":"28","author":"T Nishijima","year":"2014","journal-title":"AIDS"},{"issue":"9","key":"pone.0318068.ref037","doi-asserted-by":"crossref","first-page":"e0162320","DOI":"10.1371\/journal.pone.0162320","article-title":"Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment","volume":"11","author":"G Lapadula","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"pone.0318068.ref038","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/QAD.0000000000001070","article-title":"Urinary beta2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy","volume":"30","author":"T Nishijima","year":"2016","journal-title":"AIDS"},{"issue":"3","key":"pone.0318068.ref039","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3947\/ic.2022.0101","article-title":"The Incidence and Risk Factors of Renal Insufficiency among Korean HIV infected Patients: The Korea HIV\/AIDS Cohort Study","volume":"54","author":"JH Kim","year":"2022","journal-title":"Infect Chemother"},{"issue":"3","key":"pone.0318068.ref040","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1545109707300676","article-title":"Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study","volume":"6","author":"B Young","year":"2007","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"issue":"5","key":"pone.0318068.ref041","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s11096-015-0132-1","article-title":"Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients","volume":"37","author":"PR Quesada","year":"2015","journal-title":"Int J Clin Pharm"},{"issue":"7","key":"pone.0318068.ref042","doi-asserted-by":"crossref","first-page":"e0252768","DOI":"10.1371\/journal.pone.0252768","article-title":"Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy","volume":"16","author":"FW Chabala","year":"2021","journal-title":"PLoS One"},{"issue":"9","key":"pone.0318068.ref043","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/QAD.0000000000001065","article-title":"Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?","volume":"30","author":"P Flandre","year":"2016","journal-title":"AIDS"},{"issue":"12","key":"pone.0318068.ref044","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1093\/ndt\/gfr129","article-title":"Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients","volume":"26","author":"M Ando","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"pone.0318068.ref045","doi-asserted-by":"crossref","first-page":"e1001809","DOI":"10.1371\/journal.pmed.1001809","article-title":"Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D: A: D study","volume":"12","author":"A LJ Mocroft","year":"2015","journal-title":"PLoS medicine"},{"issue":"6","key":"pone.0318068.ref046","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1468-1293.2008.00691.x","article-title":"Spectrum of chronic kidney disease in HIV-infected patients","volume":"10","author":"LJ Campbell","year":"2009","journal-title":"HIV Med"},{"issue":"6","key":"pone.0318068.ref047","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/hiv.12729","article-title":"Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa","volume":"20","author":"P Bock","year":"2019","journal-title":"HIV Med"},{"key":"pone.0318068.ref048","first-page":"491","article-title":"Tenofovir Disoproxil Fumarate-Associated Renal Dysfunction Among Adult People Living with HIV at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, 2019: A Comparative Retrospective Cohort Study","volume":"13","author":"SG Debeb","year":"2021","journal-title":"HIV AIDS (Auckl)"},{"issue":"2","key":"pone.0318068.ref049","article-title":"Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected Nigerian patients","volume":"8","author":"BV AI Ojeh","year":"2018","journal-title":"GERMS"},{"issue":"8","key":"pone.0318068.ref050","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/QAD.0000000000001041","article-title":"Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens","volume":"30","author":"H Zachor","year":"2016","journal-title":"AIDS"},{"issue":"1","key":"pone.0318068.ref051","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s13104-019-4454-2","article-title":"Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana","volume":"12","author":"ET Nartey","year":"2019","journal-title":"BMC Res Notes"},{"issue":"2","key":"pone.0318068.ref052","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/pds.5125","article-title":"Tenofovir disoproxil fumarate associated nephrotoxicity: a retrospective cohort study at two referral hospitals in Namibia","volume":"30","author":"F Kalemeera","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0318068.ref053","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1471-2334-14-173","article-title":"Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom","volume":"14","author":"SN Pujari","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0318068.ref054","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1874613602115010073","article-title":"Incidence Rate and Time to Occurrence of Renal Impairment and Chronic Kidney Disease among Thai HIV-infected Adults with Tenofovir Disoproxil Fumarate Use","volume":"15","author":"J Visuthranukul","year":"2021","journal-title":"The Open AIDS Journal"},{"issue":"5","key":"pone.0318068.ref055","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/jac\/dkr039","article-title":"Low incidence of renal impairment observed in tenofovir-treated patients","volume":"66","author":"EP O\u2019Donnell","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"pone.0318068.ref056","doi-asserted-by":"crossref","first-page":"e0135188","DOI":"10.1371\/journal.pone.0135188","article-title":"Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar","volume":"10","author":"NT Kyaw","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"pone.0318068.ref057","doi-asserted-by":"crossref","first-page":"e22661","DOI":"10.1371\/journal.pone.0022661","article-title":"Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients","volume":"6","author":"T Nishijima","year":"2011","journal-title":"PLoS One"},{"issue":"13","key":"pone.0318068.ref058","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/QAD.0000000000001901","article-title":"Predictors of chronic kidney disease and utility of risk prediction scores in HIV-positive individuals","volume":"32","author":"EL Woolnough","year":"2018","journal-title":"AIDS"},{"issue":"5","key":"pone.0318068.ref059","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/hiv.13019","article-title":"Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score","volume":"22","author":"R Hsu","year":"2021","journal-title":"HIV Med"},{"issue":"10","key":"pone.0318068.ref060","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/03007995.2020.1816538","article-title":"Association of tenofovir disoproxil fumarate exposure with chronic kidney disease and osteoporotic fracture in US veterans with HIV","volume":"36","author":"SS Sutton","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"pone.0318068.ref061","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2893.2009.01084.x","article-title":"Reduced glomerular filtration rate but sustained virologic response in HIV\/hepatitis B co-infected individuals on long-term tenofovir","volume":"16","author":"LK Tan","year":"2009","journal-title":"J Viral Hepat"},{"issue":"2","key":"pone.0318068.ref062","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/1440-1681.12691","article-title":"Renal function in HIV\/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting","volume":"44","author":"L Milazzo","year":"2017","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"3","key":"pone.0318068.ref063","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jppr.1392","article-title":"Is the risk of tenofovir-induced nephrotoxicity similar in treatment-na\u00efve compared to treatment-experienced patients?","volume":"48","author":"JZ Low","year":"2018","journal-title":"Journal of Pharmacy Practice and Research"},{"issue":"5","key":"pone.0318068.ref064","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.nefroe.2019.09.001","article-title":"Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study","volume":"39","author":"P Domingo","year":"2019","journal-title":"Nefrologia (Engl Ed)"},{"issue":"4","key":"pone.0318068.ref065","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3349\/ymj.2017.58.4.770","article-title":"Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study","volume":"58","author":"KH Lee","year":"2017","journal-title":"Yonsei Med J"},{"issue":"8","key":"pone.0318068.ref066","article-title":"Chronic Kidney Disease in a Large National Human Immunodeficiency Virus Treatment Program","volume":"10","author":"N Paengsai","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"19","key":"pone.0318068.ref067","article-title":"Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort","volume":"9","author":"AC LR Chua","year":"2012","journal-title":"AIDS Research and Therapy"},{"issue":"2","key":"pone.0318068.ref068","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/00365548.2012.712213","article-title":"Incidence of renal toxicity in HIV-infected, antiretroviral-naive patients starting tenofovir\/emtricitabine associated with efavirenz, atazanavir\/ritonavir, or lopinavir\/ritonavir","volume":"45","author":"L TF Calza","year":"2013","journal-title":"Scandinavian journal of infectious diseases"},{"issue":"5","key":"pone.0318068.ref069","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/0897190012442718","article-title":"Renal toxicity of long-term therapy with tenofovir in HIV-infected patients","volume":"25","author":"MO CM Monteagudo-Chu","year":"2012","journal-title":"Journal of pharmacy practice"},{"issue":"2019","key":"pone.0318068.ref070","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijid.2019.03.034","article-title":"Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients","volume":"83","author":"J CJ Yang","year":"2019","journal-title":"International Journal of Infectious Diseases"},{"issue":"3","key":"pone.0318068.ref071","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0956462417722133","article-title":"Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate","volume":"29","author":"NA CE Medland","year":"2018","journal-title":"International journal of STD & AIDS"},{"issue":"1","key":"pone.0318068.ref072","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1179\/1528433614Z.0000000001","article-title":"Renal safety of coformulated tenofovir\/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study","volume":"16","author":"E C-MA Pedrol","journal-title":"HIV Clinical Trials"},{"issue":"1","key":"pone.0318068.ref073","doi-asserted-by":"crossref","first-page":"e00681","DOI":"10.1002\/prp2.681","article-title":"Effect of tenofovir containing ART on renal function in patients with moderate\/severe reduced creatinine clearance at baseline: A retrospective study at two referral hospitals in Namibia","volume":"11","author":"F GB Kalemeera","year":"2023","journal-title":"Pharmacology Research & Perspectives"},{"issue":"11","key":"pone.0318068.ref074","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/pds.4657","article-title":"Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia","volume":"27","author":"K BD Joshi","year":"2018","journal-title":"Pharmacoepidemiology and drug safety"},{"key":"pone.0318068.ref075","author":"F LH Liu","journal-title":"Determinants and incidence of chronic kidney disease on tenofovir-based antiretroviral therapy regimens: A cohort study in HIV-infected adults in South China"},{"issue":"5","key":"pone.0318068.ref076","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.4269\/ajtmh.17-0060","article-title":"Effect of Tenofovor Diproxil Fumarate on Renal Function and Urinalysis Abnormalities in HIV-Infected Cameroonian Adults","volume":"97","author":"C Fritzsche","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"pone.0318068.ref077","first-page":"301","article-title":"Chronic Kidney Disease and Associated Factors Among HIV Infected Patients Taking Tenofovir Disoproxil Fumarate Based Regimen in Ethiopia: A Hospital-Based Cross-Sectional Study","volume":"13","author":"AM Belete","year":"2021","journal-title":"HIV AIDS (Auckl)"},{"key":"pone.0318068.ref078","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12882-015-0192-4","article-title":"Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana","volume":"16","author":"DR Chadwick","year":"2015","journal-title":"BMC Nephrol"},{"issue":"1","key":"pone.0318068.ref079","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12882-020-01873-y","article-title":"Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study","volume":"21","author":"L Nyende","year":"2020","journal-title":"BMC Nephrol"},{"key":"pone.0318068.ref080","first-page":"61","article-title":"Predictors of chronic kidney disease among HIV-infected patients on highly active antiretroviral therapy at the University of Calabar Teaching Hospital, Calabar, South-South Nigeria","volume":"11","author":"HO Okpa","year":"2019","journal-title":"HIV AIDS (Auckl)"},{"issue":"4","key":"pone.0318068.ref081","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1053\/j.ajkd.2016.03.430","article-title":"HIV Infection, Tenofovir, and Urine alpha1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study","volume":"68","author":"V Jotwani","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"pone.0318068.ref082","doi-asserted-by":"crossref","first-page":"14565","DOI":"10.1038\/s41598-017-15214-x","article-title":"Prevalence and factors associated with chronic kidney disease and end-stage renal disease in HIV-1-infected Asian patients in Tokyo","volume":"7","author":"T Nishijima","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0318068.ref083","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12882-018-1130-z","article-title":"Renal dysfunction among adult HIV\/AIDS patients on antiretroviral therapy at a tertiary facility in Ghana","volume":"19","author":"D Obiri-Yeboah","year":"2018","journal-title":"BMC Nephrol"},{"issue":"1","key":"pone.0318068.ref084","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s10157-013-0817-5","article-title":"Prevalence of renal disease within an urban HIV-infected cohort in northern Italy","volume":"18","author":"L Calza","year":"2014","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"pone.0318068.ref085","doi-asserted-by":"crossref","first-page":"e0147724","DOI":"10.1371\/journal.pone.0147724","article-title":"A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection","volume":"11","author":"S Likanonsakul","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"pone.0318068.ref086","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5897\/JAHR2019.0498","article-title":"Assessment of renal dysfunction and associated factors among patients on Tenofovir based antiretroviral treatment at Gondar University Hospital, North West Ethiopia: Retrospective institution based cross sectional study","volume":"12","author":"E DE Ahmed","year":"2020","journal-title":"Journal of AIDS and HIV Research"},{"issue":"37","key":"pone.0318068.ref087","doi-asserted-by":"crossref","first-page":"e7421","DOI":"10.1097\/MD.0000000000007421","article-title":"Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals","volume":"96","author":"J BA Juega-Mari\u00f1o","year":"2017","journal-title":"Medicine"},{"issue":"2020","key":"pone.0318068.ref088","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/8378947","article-title":"Renal dysfunction among HIV-infected patients on antiretroviral therapy in Dar es Salaam, Tanzania: a cross-sectional study","volume":"2020","author":"O RP Mwemezi","year":"2020","journal-title":"International journal of nephrology"},{"issue":"8","key":"pone.0318068.ref089","article-title":"Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate\u2265 60 ml\/min per 1.73 m2","volume":"27","author":"J CA Reynes","year":"2013","journal-title":"Aids"},{"issue":"2020","key":"pone.0318068.ref090","first-page":"1","article-title":"Determinants of risk factors for renal impairment among HIV-infected patients treated with tenofovir disoproxil fumarate-based antiretroviral regimen in Southern Vietnam","volume":"2020","author":"CQ NH Hoang","year":"2020","journal-title":"BioMed Research International"},{"issue":"6","key":"pone.0318068.ref091","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/apc.2009.0326","article-title":"Prevalence and factors associated with renal dysfunction among HIV-infected patients","volume":"24","author":"N GA Crum-Cianflone","year":"2010","journal-title":"AIDS patient care and STDs"},{"key":"pone.0318068.ref092","unstructured":"Group TWB. World Bank Country and Lending Groups 2024 [https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups."},{"issue":"2024","key":"pone.0318068.ref093","first-page":"1","article-title":"A review of Tenofovir Disoproxil Fumarate associated nephrotoxicity among People Living with HIV: Burden, risk factors and solutions","volume":"25","author":"ES RV Asirvatham","year":"2023","journal-title":"Clinical Epidemiology and Global Health"},{"issue":"9","key":"pone.0318068.ref094","first-page":"e45787","article-title":"Tenofovir-Induced Renal Dysfunction Among HIV-Infected Patients: A Systematic Review","volume":"15","author":"YM Shivakumar","year":"2023","journal-title":"Cureus"},{"issue":"12","key":"pone.0318068.ref095","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1128\/AAC.38.12.2743","article-title":"Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis","volume":"38","author":"JL BC Martin","year":"1994","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"9","key":"pone.0318068.ref096","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00228-014-1712-z","article-title":"Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention","volume":"70","author":"A Jafari","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"pone.0318068.ref097","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2055-6640(20)30248-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?","volume":"4","author":"A HS Hill","year":"2018","journal-title":"Journal of Virus Eradication"},{"key":"pone.0318068.ref098","doi-asserted-by":"crossref","first-page":"2325958220919231","DOI":"10.1177\/2325958220919231","article-title":"A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide","volume":"19","author":"C Wassner","year":"2020","journal-title":"J Int Assoc Provid AIDS Care"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0318068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T13:43:12Z","timestamp":1738849392000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0318068"}},"subtitle":[],"editor":[{"given":"Tarek Samy","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":98,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0318068","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}